We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

QuidelOrtho

Develops, manufactures and markets rapid diagnostic tests that focus on infectious diseases, reproductive health, and... read more Featured Products: More products

Download Mobile App




Ortho and Thermo Fisher Enter Into Partnership for Quality Control Products

By LabMedica International staff writers
Posted on 08 Jul 2021
Ortho Clinical Diagnostics (Raritan, NJ, USA) has entered into a distribution agreement with Thermo Fisher Scientific Inc. More...
(Waltham, MA, USA) to provide and support MAS Quality Controls and LabLink xL Quality Assurance Software through Ortho's VITROS QC Solutions to VITROS System customers worldwide.

The VITROS QC Solutions will provide customers with a combination of Ortho Clinical Diagnostics controls and Thermo Scientific MAS Quality Controls to bring a complete quality control solution to the laboratory. Featuring consolidated, liquid-ready, Gen-Specific Value assignment along with LabLink xL, a web-based quality assurance program that provides real-time quality control monitoring with automatic data entry upload and audit-friendly reports. VITROS System customers will have access to the unique Gen-Specific Peer Group evaluation, that is currently unavailable through any other quality control program. Paired with the proprietary technologies and benefits only available on VITROS Systems, VITROS QC Solutions improves workflows and drives efficiency, enabling labs to streamline operations without sacrificing quality.

"Ortho continues to bring innovative solutions to market, like our latest VITROS QC Solutions, that allow labs to take charge of their operations with improved ease of use and optimized product utilization – saving them time and money," said Bryan Hanson, Head of Clinical Laboratories Business Unit at Ortho Clinical Diagnostics. "Through this agreement with Thermo Fisher Scientific, we can provide laboratories with better solutions, allowing them to maximize their laboratory productivity."

Related Links:
Ortho Clinical Diagnostics
Thermo Fisher Scientific Inc.



Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Gold Member
Automatic Hematology Analyzer
CF9600
New
Immunofluorescence Analyzer
IFA System
New
Pipette Calibration System
Artel PCS®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.